• 1
    Nagashima F, Ohtsu A, Yoshida S, Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005; 8: 611.
  • 2
    Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 40049.
  • 3
    Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol 1990; 81: 6673.
  • 4
    Muneoka K, Shirai Y, Yokoyama N, Wakai T, Hatakeyama K. 5-Fluorouracil cardiotoxicity induced by α-fluoro-β-alanine. Int J Clin Oncol 2005; 10: 4413.
  • 5
    Kinoshita T, Nashimoto A, Yamamura Y et al . Feasibility study of adjuvant chemotherapy with S-1 (TS-1; FT, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 2004; 7: 1049.
  • 6
    Nakata B, Mitachi Y, Tsuji A et al . Combination therapy of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer: a multicenter phase I study. Clin Cancer Res 2004; 10: 16649.
  • 7
    Yoshida K, Ninomiya M, Takakura N et al . Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 34027.
  • 8
    Ueda Y, Yamagishi H, Ichikawa D et al . Phase I study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 2005; 69: 2618.
  • 9
    Inokuchi M, Yamashita T, Yamada H et al . Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006; 94: 11305.
  • 10
    Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 (combined drug of FT, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B 1997; 691: 95104.
  • 11
    Yamada Y, Hamaguchi T, Goto M et al . Plasma concentration of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 81620.
  • 12
    Takechi T, Uchida J, Fujioka A, Fukushima M. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 1997; 11: 10414.
  • 13
    Hayashi K, Isobe Y, Honda I et al . Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006; 9: 5166.
  • 14
    Hundahl SA, Menck HR, Mansour EG, Winchester DP. The national cancer data base report on gastric carcinoma. Cancer 1997; 80: 233341.
  • 15
    Hirata K, Horikoshi N, Aiba K et al . Pharmacokinetics study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 20005.
  • 16
    Tsuruoka Y, Kamano T, Kitajima M et al . Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. Anti-Cancer Drug 2006; 17: 3939.
  • 17
    Fety R, Rolland F, Barberi-Heyob M et al . Clinical impact of pharmacokinetically guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 203945.
  • 18
    Ajani JA, Faust J, Ikeda K et al . Phase I pharmacokinetics study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 695765.
  • 19
    Van Groeningen CJ, Peters GJ, Schornagel JH et al . Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 27729.
  • 20
    Cohen SJ, Leichman CG, Yeslow G et al . Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8: 211622.
  • 21
    Maehara Y, Takeuchi H, Oshiro T et al . Effect of gastrectomy on the pharmacokinetics of FT, uracil, and 5-fluorouracil after oral administration of a 1 : 4 FT and uracil combination. Cancer Chemother Pharmacol 1994; 33: 4459.
  • 22
    Yoshisue K, Masuda H, Matsushima E et al . Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of FT, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos 2000; 28: 11627.